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ABSTRACT
Objective Serrated polyposis syndrome (SPS) is
accompanied by an increased risk of colorectal cancer
(CRC). Patients fulﬁlling the clinical criteria, as deﬁned
by the WHO, have a wide variation in CRC risk. We
aimed to assess risk factors for CRC in a large cohort of
patients with SPS and to evaluate the risk of CRC during
surveillance.
Design In this retrospective cohort analysis, all patients
with SPS from seven centres in the Netherlands and two
in the UK were enrolled. WHO criteria were used to
diagnose SPS. Patients who only fulﬁlled WHO criterion-
2, with IBD and/or a known hereditary CRC syndrome
were excluded.
Results In total, 434 patients with SPS were included
for analysis; 127 (29.3%) were diagnosed with CRC. In
a per-patient analysis ≥1 serrated polyp (SP) with
dysplasia (OR 2.07; 95% CI 1.28 to 3.33), ≥1
advanced adenoma (OR 2.30; 95% CI 1.47 to 3.67)
and the fulﬁlment of both WHO criteria 1 and 3 (OR
1.60; 95% CI 1.04 to 2.51) were associated with CRC,
while a history of smoking was inversely associated with
CRC (OR 0.36; 95% CI 0.23 to 0.56). Overall, 260
patients underwent surveillance after clearing of all
relevant lesions, during which two patients were
diagnosed with CRC, corresponding to 1.9 events/1000
person-years surveillance (95% CI 0.3 to 6.4).
Conclusion The presence of SPs containing dysplasia,
advanced adenomas and/or combined WHO criteria 1
and 3 phenotype is associated with CRC in patients with
SPS. Patients with a history of smoking show a lower
risk of CRC, possibly due to a different pathogenesis of
disease. The risk of developing CRC during surveillance
is lower than previously reported in literature, which may
reﬂect a more mature multicentre cohort with less
selection bias.
BACKGROUND
Colorectal cancer (CRC) is one of the main cancer-
related causes of morbidity and mortality in the
Western world.1 As CRC arises from premalignant
polyps, the detection and resection of these lesions
decrease both CRC incidence and mortality.2
A growing body of evidence shows that 15%–30%
of all CRCs arise from serrated polyps (SPs) rather
than adenomas, via the serrated neoplasia
pathway.3–5 This pathway is characterised by several
genetic and epigenetic changes of which the most
well-described alterations are a mutation in the
BRAF-oncogene and hypermethylation of promoter
regions of tumour suppressor genes and subsequent
silencing of these genes.6–9 The recent classiﬁcation
of the WHO classiﬁes SPs into the subgroups
hyperplastic polyps (HPs), sessile serrated aden-
omas/polyps (SSA/Ps) with or without dysplasia,
Signiﬁcance of this study
What is already known on this subject?
▸ Serrated polyposis syndrome is accompanied by
an increased risk of colorectal cancer.
▸ Patients fulﬁlling the clinical criteria for
serrated polyposis syndrome have a wide
variation in colorectal cancer risk.
▸ Colorectal cancer risk factors in these patients
are not yet well deﬁned.
What are the new ﬁndings?
▸ Serrated polyps containing dysplasia, advanced
adenomas and/or a combined WHO criteria 1
and 3 phenotype are associated with colorectal
cancer in patients with serrated polyposis
syndrome.
▸ Patients with serrated polyposis having a
history of smoking show a lower risk of
colorectal cancer, possibly due to a different
pathogenesis of disease.
▸ The risk of colorectal cancer during surveillance
and after clearing of all relevant lesions is
lower than suggested earlier.
How might it impact on clinical practice in
the foreseeable future?
▸ The clinical risk factors that we discovered in
the current study could help to risk stratify
patients with serrated polyposis for different
surveillance intervals in order to decrease
patient burden as well as the incidence of
colonoscopy interval colorectal cancer.
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and traditional serrated adenomas (TSAs).10 Diminutive HPs
located in the rectosigmoid are generally considered benign,
whereas larger and/or proximally located HPs, and all SSA/Ps
and TSAs are considered to possess a higher neoplastic
potential.11 12
Serrated polyposis syndrome (SPS) is a syndrome charac-
terised by multiple SPs located throughout the colon and is
accompanied by an increased risk of CRC.10 The prevalence of
SPS in the general population is largely unknown; however,
rates in colonoscopy screening populations of 1:2000 have been
reported.13 In fecal occult blood test (FOBT)-based population
screening, the prevalence of SPS may exceed 1:300 participants,
demonstrating the importance for endoscopists to recognise and
diagnose this syndrome.13 As germline mutations for SPS are
unknown, this disease has been clinically deﬁned by the WHO
by the presence of at least ﬁve SPs proximal to the sigmoid
colon, of which two are ≥10 mm in diameter (WHO
criterion-1), the presence of one SP proximal to the sigmoid
and a ﬁrst-degree relative (FDR) with SPS (WHO criterion-2)
and/or 20 SPs or more, irrespective of size, but located through-
out the colorectum (WHO criterion-3).10 Although WHO
criterion-2 is rarely used, this clinical deﬁnition of the WHO
leads to a very heterogeneous group of patients with SPS, with a
wide variation in CRC risk. CRC risk for patients at their ﬁrst
presentation with SPS is reported up to 50%, while several
retrospective studies have shown that these patients also have an
increased risk of developing CRC under endoscopic surveil-
lance.14–18 However, the actual risk of CRC for patients with
SPS is probably overestimated in these small studies, due to
selection bias and non-structured surveillance. A recent pro-
spective study in 41 patients showed that, under annual surveil-
lance, none of the patients developed CRC during 5-year
follow-up.19
Large multicentre studies are needed to estimate the actual
CRC incidence under surveillance in daily practice. Moreover, it
is important to characterise those patients with SPS at increased
CRC risk, in order to enable personalised treatment and surveil-
lance protocols. The aim of this study was to assess CRC risk
factors in a large cohort of patients with SPS and to evaluate the
overall risk of CRC during surveillance.
METHODS
Study design and population
This is a retrospective international multicentre cohort study.
Patients were enrolled from seven centres in the Netherlands
and two centres in the UK. In each participating centre, a search
was performed for patients with multiple SPs in their medical
history. Data were retrieved from medical charts, pathology and
endoscopy reports and hereditary CRC databases to enable the
registration of as much patients as possible. Data from 1993 to
2015 were included for analysis. Patients were included based
on a retrospective polyp count of all lesions. Patients who ful-
ﬁlled 2010 WHO criterion-1 and/or WHO criterion-3 for the
diagnosis of SPS were eligible for inclusion in this study. Patients
who only fulﬁlled WHO criterion-2 were excluded from the
analysis. The clinical characteristics of these patients are pre-
sented in online supplementary appendix 2 separately. Patients
with IBD and/or patients with a known germline adenomatous
polyposis coli (APC) mutation, a known mutation in one of the
mismatch repair genes (Lynch syndrome) or a known biallelic
Mut-YH mutation were also excluded. The study protocol was
presented to the local institutional review board (IRB) of the
Academic Medical Centre for ethical approval. The IRB decided
that formal revision was not required for this study, in
agreement with the Dutch Medical Research Involving Human
Subjects Act, since patient data were retrieved retrospectively
and no additional interventions were performed for the purpose
of this study. Formal ethical committee approval was not
required for the UK sites for the same reasons as the Dutch
cohort but each site sought and received local research and
development department approval. This study was carried out
in accordance with the Helsinki Declaration.20
Clinical characteristics
In each participating centre, data on patient age, gender,
smoking status and body mass index (BMI) were gathered from
medical charts. Medical charts were also used to gather patient
and familial history records of CRC and extracolonic cancers.
Colonoscopy reports and surgery reports with corresponding
pathology reports were used to collect information regarding
the number, size, location and type of colonic polyps detected
per patient. These reports were also used to deﬁne the initial
clinical presentation (symptomatic, familial risk or population
screening), the number of colonoscopies, the time interval
between colonoscopies, the date of SPS diagnosis and the type
as well as the reason for surgical colonic resections, if applic-
able. Data were collected and stratiﬁed as follows: before SPS
diagnosis, at SPS diagnosis or during surveillance. The surveil-
lance period was deﬁned as the period after complete endo-
scopic and/or surgical clearing of all clinically relevant SPs (all
lesions above 5 mm). As a result, lesions that were detected
between the diagnosis of SPS and the clearing of all relevant
polyps were included in the ‘at diagnosis’ group. All data were
anonymised per centre before being uploaded to a central
database.
Histopathology
Histopathology was considered as the reference standard in this
study. No centralised histopathology revision was performed.
All detected lesions were assigned as SPs, adenomas or as ‘other
type of polyp’. All HPs, SSA/Ps and TSAs were accounted as SPs
but were not taken into account separately in the analyses, given
the retrospective design of this study and the high interobserver
variability between pathologists in the differentiation of these
polyp subtypes.21 22 SPs were subdivided into SPs without dys-
plasia and those with dysplasia. Adenomas were subdivided into
non-advanced adenomas and advanced adenomas. Adenomas
≥10 mm, with high-grade dysplasia and/or a villous component
were accounted as advanced adenomas.
Study outcomes and statistical analysis
The primary objective of this study was to evaluate clinical risk
factors associated with CRC in patients with SPS. Both clinical
risk factors as well as colonoscopy risk factors were evaluated in
a per-patient analysis. In case of a median number of detected
lesions per patient of >0, risk factors were handled as ordinal
or continuous variable. In case of a median number of detected
lesions of 0, risk factors were dichotomised and treated as a
binary variable. For each risk factor, the univariate association
with the occurrence of CRC was calculated and presented as
OR with 95% CI. Multivariable logistic regression was used to
assess the adjusted associations between these risk factors and
the presence of CRC. All risk factors that showed a signiﬁcant
association with CRC in the univariate analysis were included in
the multivariable analyses, as well as age at SPS diagnosis.
Missing data were assumed to be missing at random. Multiple
imputation, using a multivariable model, was performed to
adjust for missing values.23 Analyses were performed using 10
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imputed datasets. A sensitivity analysis was performed, in which
patients diagnosed with CRC before diagnosed with SPS were
excluded. Secondary objective of this study was to evaluate the
risk of developing CRC during surveillance after the clearing of
all relevant lesions. Kaplan–Meier survival analysis was used to
calculate the 5-year cumulative incidence for CRC.
Furthermore, the incidence rate of CRC during surveillance was
measured. Statistical analyses were performed using SPSS statis-
tics (V.21; SPSS, Chicago, Illinois, USA) and R (V.2.15.0) (The R
Foundation for Statistical Computing). A two-sided p value
<0.05 was considered signiﬁcant in the analyses.
RESULTS
Patient characteristics
In total, 480 patients were identiﬁed who fulﬁlled at least one
of the WHO criteria for SPS (ﬁgure 1). Of these patients, only
27 fulﬁlled WHO criterion-2, 14 also had been diagnosed with
IBD and 5 had a hereditary CRC syndrome (4 patients with
Lynch syndrome and 1 with Mut-YH associated polyposis).
These patients were excluded, resulting in a total of 434 patients
eligible for inclusion in the analysis, of whom 283 patients
(65.2%) were diagnosed from 2010 onwards. Of these 434
patients, 292 (67.3%) were included in a Dutch centre and 142
(32.7%) in a British centre.
Baseline characteristics of patients are presented in table 1.
The median age of patients at diagnosis was 60.8 years (IQR
51.7–67.0) and 211 patients (48.6%) were male. In total, 117
patients (27.0%) fulﬁlled WHO criterion-1 only, 179 patients
(41.2%) fulﬁlled WHO criterion-3 only and 138 patients
(31.8%) fulﬁlled both WHO criteria 1 and 3. First clinical pres-
entation was: ‘symptomatic’ for 308 patients (71.0%), ‘familial
cancer risk’ for 69 patients (15.9%) and ‘population screening’
for 57 patients (13.1%). In total, 182 patients (56.9%) had a
history of smoking, 41 patients (16.2%) had a BMI ≥30, 149
patients (38.4%) had at least one FDR with CRC and 25
patients (5.9%) had at least one FDR that was also diagnosed
with SPS (WHO criterion-1 and/or WHO criterion-3).
The overall median number of detected SPs (detected up to
diagnosis and during surveillance) per patient was 29 (IQR 17–
50). The median number of detected lesions was 14 (IQR 7–25)
for SPs proximal to the rectosigmoid, 3 (IQR 1–5) for SPs
≥10 mm and 3 (0–5) for SPs ≥10 mm proximal to the rectosig-
moid. In total, 330 patients (76.0%) were diagnosed with at
least one SP ≥10 mm, 310 patients (71.4%) with at least one SP
≥10 mm proximal to the rectosigmoid and 114 patients
(26.3%) with at least one SP-containing dysplasia. The overall
median number of detected adenomas per patient was 2 (IQR
0–5). In total, 324 patients (74.7%) were also diagnosed with at
least one adenoma and 153 patients (35.3%) were diagnosed
with at least one advanced adenoma.
Overall, 127/434 patients (29.3%) were diagnosed with CRC,
of whom 8/434 patients (1.8%) were diagnosed with two syn-
chronous primary CRCs and 9/434 patients (2.1%) with two
metachronous CRCs (table 2). The median age at ﬁrst diagnosis
of CRC was 60.8 years (range 20.3–84.7). In total 33/117
patients (28.2%) diagnosed with WHO criterion-1, 44/179
patients (24.6%) diagnosed with WHO criterion-3 and 50/138
patients (36.2%) diagnosed with both WHO criteria 1 and 3
were diagnosed with CRC (p=0.07). With regard to ﬁrst
Figure 1 Study ﬂowchart. CRC, colorectal cancer; SPS, serrated
polyposis syndrome.
Table 1 Baseline characteristics
Total cohort size; n 434
Age at diagnosis; median (IQR) 60.8 (51.7–67.0)
Male gender; n (%) 211 (48.6)
WHO subtype; n (%)
Type 1 117 (27.0)
Type 3 179 (41.2)
Type 1+3 138 (31.8)
Smoking status; n (%)
Current smoker 126 (39.4)
Former smoker 56 (17.5)
No smoker 138 (43.1)
Missing 114
BMI; n (%)
≥30 kg/m2 41 (16.2)
<30 kg/m2 212 (83.8)
Missing 181
FDR with CRC; n (%)
Yes 149 (38.4)
No 239 (61.6)
Missing 46
FDR with SPS; n (%)
Yes 25 (5.9)
No 409 (94.1)
Clinical presentation; n (%)
Symptoms 308 (71.0)
Familial cancer risk 69 (15.9)
Population screening 57 (13.1)
Overview of detected polyps per patient
No. of SPs; median (IQR) 29 (17–50)
No. of SPs proximal to the rectosigmoid; median (IQR) 14 (7–25)
No. of SPs ≥10 mm; median (IQR) 3 (1–5)
Patients with at least 1 SP ≥10 mm; n (%) 330 (76.0)
No. of SPs ≥10 mm proximal to the rectosigmoid; median
(IQR)
3 (0–5)
Patients with at least 1 SP ≥10 mm proximal to the
rectosigmoid; n (%)
310 (71.4)
No. of SPs containing dysplasia; median (range) 0 (0–18)
Patients with at least 1 SP-containing dysplasia; n (%) 114 (26.3)
No. of adenomas; median (IQR) 2 (0–5)
Patients with at least 1 adenoma; n (%) 324 (74.7)
No. of advanced adenomas; median (range) 0 (0–6)
Patients with at least 1 advanced adenoma; n (%) 153 (35.3)
BMI, body mass index; CRC, colorectal cancer; FDR, first-degree relative; SPs, serrated
polyps; SPS, serrated polyposis syndrome.
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clinical presentation, 13/57 patients (22.8%) who presented via
population screening, 110/308 patients (35.7%) who presented
with symptoms and 4/69 patients (5.8%) who were screened for
a familial CRC risk were diagnosed with CRC (p<0.001). In
total, 74 CRCs (51.4%) were detected before the diagnosis of
SPS, 68 CRCs (47.2%) at the time of diagnosis of SPS and 2
CRCs (1.4%) during SPS surveillance. In total, 75/144 CRCs
(52.1%) were located in the left-sided colon and 69/144
(47.9%) in the right-sided colon. The different SPS phenotypes
showed no statistically signiﬁcant difference in the location of
CRC (p=0.53). In total 69/144 CRCs (47.9%) were diagnosed
in the rectosigmoid. Median age at diagnosis of CRC in these
patients was 58.0 (range 20.3–79.2) versus 63.7 (range 26.9–
84.7) for patients diagnosed with CRC proximal to the rectosig-
moid (p=0.03). No difference was found for gender (48.5% vs
37.3% male; p=0.20).
Risk factors for CRC
Risk factors for CRC in patients with SPS are presented in
table 3. Univariate analyses showed an association with CRC in
patients who were diagnosed with at least one SP-containing
dysplasia (OR 2.34; 95% CI 1.48 to 3.70; p<0.001) and for
patients with at least one advanced adenoma (OR 2.46; 95% CI
1.59 to 3.80; p<0.001). Patients who fulﬁlled both WHO cri-
teria 1 and 3 also showed an increased CRC risk (OR 1.62;
95% CI 1.05 to 2.49; p=0.03). The cumulative number of SPs
as well as adenomas was not signiﬁcantly associated with the
diagnosis of CRC. Patients with CRC were signiﬁcantly older at
SPS diagnosis when compared with patients without CRC
(p<0.001). A history of smoking was inversely associated with
CRC (OR 0.48; 95% CI 0.30 to 0.78; p<0.01).
Multiple logistic regression analysis showed similar results.
Patients having at least one SP with dysplasia (OR 2.07; 95% CI
1.28 to 3.33; p<0.01), at least one advanced adenoma (OR
2.30; 95% CI 1.47 to 3.67; p<0.001) and patients who fulﬁlled
both WHO criteria 1 and 3 (OR 1.60; 95% CI 1.04 to 2.51;
p<0.05) had an increased risk to be diagnosed with CRC,
adjusted for the confounder of age at SPS diagnosis. Patients
with a history of smoking had a lower risk of CRC (OR 0.36;
95% CI 0.23 to 0.56; p<0.001). The decreased risk of CRC in
patients with a history of smoking was found both for women
(adjusted OR 0.49; 95% CI 0.26 to 0.95) and for men (adjusted
OR 0.30; 95% CI 0.15 to 0.60). Subsequent analysis showed
that these patients signiﬁcantly more often fulﬁlled WHO
criterion-3 only (OR 1.73; 95% CI 1.10 to 2.74; p=0.02). The
performed sensitivity analysis showed no structural differences
in the association between potential risk factors and CRC.
Clinical management of SPS
Of the 434 patients, 403 (92.9%) received clearing of all clinic-
ally relevant lesions, 28 patients were not yet cleared and 3
patients died from CRC before clearing was accomplished
(table 4). The median time from diagnosis up to clearing of all
relevant lesions was 1.5 months (IQR 0–8.7). In total, 95/403
patients (23.6%) needed surgery during the clearing phase, of
which 56 (58.9%) was due to CRC, 30 (31.6%) was due to
polyp burden, 8 (8.4%) was due to an unresectable polyp and 1
Table 2 Characteristics of patients with CRC
All patients with CRC; n (%) 127 (29.3)
Patients with two synchronous primary CRCs; n (%) 8 (1.8)
Patients with metachronous CRC; n (%) 9 (2.1)
Age at diagnosis first CRC; median (range) 60.8 (20.3–84.7)
WHO subtype; n (%)
Criterion-1 33 (26.0)
Criterion-3 44 (34.6)
Criterion 1+3 50 (39.4)
Moment of diagnosis CRC (144 cancers); n (%)*
Before diagnosis SPS 74 (51.4)
At diagnosis SPS 68 (47.2)
During surveillance 2 (1.4)
Location CRC (144 cancers); n (%)
Caecum 14 (9.7)
Ascending colon 31 (21.5)
Transverse colon 24 (16.7)
Descending colon 6 (4.2)
Rectosigmoid 69 (47.9)
*Carcinomas detected between diagnosis of SPS and clearing of all relevant polyps
were included in the ‘at diagnosis’ group.
CRC, colorectal cancer; SPS, serrated polyposis syndrome.
Table 3 Risk factors for CRC in 434 patients with SPS
Patients with
CRC (n=127)
Patients without
CRC (n=307)
Univariate
OR (95% CI) p Value
Multivariable
OR (95% CI) p Value
Age at diagnosis SPS in years; median (IQR) 63.6 (58.1–69.6) 59.4 (48.2–65.4) 1.04 (1.02 to 1.06) <0.001 1.03 (1.01 to 1.05) <0.001
Male gender; n (%) 55 (43.3) 156 (50.8) 0.74 (0.49 to 1.12) 0.16
A history of smoking; n (%)* 43 (44.3) 139 (62.3) 0.48 (0.30 to 0.78) <0.01 0.36 (0.23 to 0.56) <0.001
BMI ≥30; n (%)* 9 (10.6) 32 (19.0) 0.50 (0.22 to 1.07) 0.09
At least one FDR with CRC; n (%)* 38 (34.2) 111 (40.1) 0.78 (0.49 to 1.23) 0.29
At least one FDR with SPS; n (%) 5 (4.1) 20 (6.7) 0.60 (0.20 to 1.51) 0.31
No. of SPs; median (IQR) 29 (18–46) 29 (17–52) 1.00 (0.99 to 1.01) 0.67
No. of SPs ≥10 mm; median (IQR) 3 (1–5) 3 (1–5) 0.99 (0.96 to 1.03) 0.69
No. of SPs proximal to the rectosigmoid; median (IQR)† 15 (8–27) 13 (7–25) 1.00 (0.99 to 1.01) 0.94
No. of SPs ≥10 mm proximal to the rectosigmoid; median (IQR)† 3 (1–5) 2 (1–4) 1.00 (0.96 to 1.04) 0.99
At least 1 SP containing dysplasia; n (%) 48 (37.8) 66 (21.5) 2.34 (1.48 to 3.70) <0.001 2.07 (1.28 to 3.33) <0.01
No. of adenomas; median (IQR) 2 (1–5) 2 (0–5) 1.03 (0.98 to 1.08) 0.30
At least 1 advanced adenoma; n (%) 64 (50.4) 89 (29.0) 2.46 (1.59 to 3.80) <0.001 2.30 (1.47 to 3.67) <0.001
Fulfilling WHO criteria 1 and 3; n (%) 50 (39.4) 88 (28.7) 1.62 (1.05 to 2.49) 0.02 1.60 (1.04 to 2.51) <0.05
*Referred to patients in which the variable was available.
†Proximal is defined as proximal to the rectosigmoid.
BMI, body mass index; CRC, colorectal cancer; FDR, first-degree relative; SPs, serrated polyps; SPS, serrated polyposis syndrome.
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(1.1%) was as a result of a perforation caused by polypectomy.
For those 308 patients who could be treated endoscopically, a
median number of 2 clearing colonoscopies (IQR 1–3) were
needed.
A total of 260 patients (59.9%) underwent surveillance after
clearing of all lesions >5 mm with a median follow-up of
3.2 years (IQR 1.6–5.7) and a median interval between colonos-
copies of 1.2 years (IQR 1.0–1.6) (table 4). As mentioned, two
patients were diagnosed with CRC during surveillance, which
corresponds to an incidence rate of 1.9 events/1000 person-
years of surveillance (95% CI 0.3 to 6.4). The 5-year cumulative
incidence for CRC during surveillance was 1.5% (95% CI 0%
to 3.7%). The clinical characteristics of the two patients who
developed CRC during surveillance are presented in online sup-
plementary appendix 1. A total of 11/260 patients (4.2%)
needed surgery during surveillance: 1 patient due to CRC, 5
patients due to polyp burden, 4 patients due to an unresectable
polyp and 1 patient as result of a perforation after polypectomy.
DISCUSSION
In this large multicentre study, we evaluated risk factors asso-
ciated with CRC in patients with SPS and assessed the overall
risk of developing CRC during surveillance. The presence of at
least one SP-containing dysplasia, at least one advanced
adenoma and/or a combined WHO criteria 1 and 3 phenotype
was associated with CRC. Conversely, patients with a history of
smoking showed an inverse association with CRC, possibly due
to a different pathogenesis of disease. The incidence rate of
CRC during surveillance and after clearing of all relevant
lesions was 1.9 events/1000 person-years of surveillance (95%
CI 0.3 to 6.4), corresponding to a 5-year cumulative risk of
1.5% (95% CI 0% to 3.7%).
In the current study, analyses were performed in the largest
cohort of patients to date, enabling robust estimates for both
CRC risk factors as well as CRC incidence during surveillance.
This study has an international multicentre cohort design and
included both patients from academic and from non-academic
hospitals in the Netherlands and the UK. Nevertheless, several
limitations have to be acknowledged. First, this study has a
retrospective design. As a result, quality assurance of retrieved
data was limited and this study might be subject to certain ascer-
tainment bias in patient selection. Also, due to the retrospective
design of the study, an established, uniform surveillance proto-
col was not in place, which may have introduced another
element of bias. Despite the challenge of missing data, multiple
imputation enabled the evaluation of all patients in the multi-
variable analysis. Second, due to logistic heterogeneity within
centres, we were unable to perform a uniform search within the
participating centres. Most centres already had a well-
documented prospective registry of SPS patients. These patients
form the vast majority in the analysis. In the other centres, local
computer systems were used to identify patients with multiple
SPs. For these centres, certain patients might have been missed,
imposing a risk of selection bias. A third limitation in this study
is the fact that histopathology of the colonic lesions was not
revised centrally by a panel of gastrointestinal pathologists.
Several studies showed that the interobserver agreement
between pathologists in the differentiation of SSA/Ps and HPs is
considered moderate to low.21 22 24 25 Therefore, individual
analysis for the risk of SSA/Ps and HPs separately would prob-
ably have resulted in biased and unreliable results. To overcome
this limitation, we have decided to appraise all SSA/Ps, HPs as
well as TSAs as identical lesions and to perform an overarching
analysis based on polyp location, size and the presence of dys-
plasia. The same decision was made in the most recent
European Society of Gastrointestinal Endoscopy guideline for
post-polypectomy surveillance after the resection of SPs.26 The
presence of dysplasia as well as polyp size was taken into
account in this guideline. However, due to the same histopatho-
logical restrictions, surveillance intervals were not based on
histopathological subclassiﬁcation. Taken these considerations
into account, the external validity of this study seems to be rea-
sonably founded.
Several studies have reported on the risk of CRC in patients
with SPS, demonstrating a variable risk, ranging from 7% to
70%.14 17 18 27–31 The overall prevalence of CRC in our study
(29%) was largely comparable with the risk that was presented
in the three largest cohorts till date (26%–29%).14 27 30
However, due to the retrospective design of these studies and
imposed selection bias, the CRC prevalence in these studies
probably is a poor proxy for the real prevalence of disease. In a
subsequent analysis, we demonstrated that the risk of CRC at
presentation largely depends on the ﬁrst clinical presentation. In
total, 22.8% of patients who presented via population screen-
ing, 35.7% of patients who presented with symptoms and 5.8%
of patients who were identiﬁed due to a familial CRC risk were
diagnosed with CRC (p<0.001). These results suggest that the
Table 4 Clinical management of patients with serrated polyposis
syndrome
No. of patients who received clearing of all relevant lesions 403
Time from diagnosis up to clearing (months); median (IQR) 1.5 (0–8.7)
No. of patients who received surgery during clearing; n (%) 95 (23.6)
Reason surgery during clearing; n (%)
CRC 56 (58.9)
Polyp burden 30 (31.6)
Unresectable polyp 8 (8.4)
Perforation due to polypectomy 1 (1.1)
No. of needed clearing colonoscopies; median (IQR)* 2 (1–3)
No. of patients who received surveillance after clearing of all
polyps
260
Follow-up time since clearing of all polyps (years); median
(IQR)†
3.2 (1.6–5.7)
No. of colonoscopies during surveillance; median (IQR)† 2 (1–4)
Interval between surveillance colonoscopies (years); median
(IQR)†
1.2 (1.0–1.6)
No. of patients who received surgery during surveillance; n (%) 11 (4.2)
Reason surgery during surveillance; n (%)
CRC 1 (9.1)
Polyp burden 5 (45.4)
Unresectable polyp 4 (36.4)
Perforation due to polypectomy 1 (9.1)
Overview of detected polyps during surveillance per patient†
No. of SPs; median (IQR) 7 (2–18)
No. of SPs proximal to the rectosigmoid; median (IQR) 2 (0–7)
No. of large SPs; median (IQR) 0 (0–1)
Patients with at least 1 SP ≥10 mm; n (%) 70 (26.9)
No. of adenomas; median (IQR) 0 (0–2)
Patients with at least 1 adenoma; n (%) 122 (46.9)
Patients with at least 1 SP ≥10 mm proximal to the
rectosigmoid; n (%)
65 (25.0)
Patients with at least 1 SP-containing dysplasia; n (%) 16 (6.2)
Patients with at least 1 advanced adenoma; n (%) 20 (7.7)
*Referred to the 308 patients who did not receive surgery during clearing.
†Referred to the 260 patients who received surveillance after clearing of all polyps.
CRC, colorectal cancer; SPs, serrated polyps.
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overall CRC risk in not-yet-diagnosed asymptomatic patients
with SPS is probably overestimated in previous studies as well as
in the current report.14 17 18 27–31 Few studies have tried to risk
stratify SPS patients based on clinical risk factors.30 31 In a large
cohort of 115 patients with SPS, the risk of CRC was evaluated,
stratiﬁed for phenotype: few large right-sided polyps, many
small left-sided polyps or a pancolonic phenotype.30 These phe-
notypes largely overlap with those presented in the current
study. In this study a signiﬁcant difference for CRC risk between
the described phenotypes could not be detected.30 However, we
demonstrated that patients who fulﬁlled both WHO criteria 1
and 3 were at increased risk to be diagnosed with CRC, com-
pared with patients who fulﬁlled WHO criterion-1 or WHO
criterion-3 only (adjusted OR 1.60; 95% CI 1.04 to 2.51;
p<0.05). In a large cross-sectional study, risk factors of CRC
were evaluated in 151 patients with at least ﬁve SPs outside the
rectum and most of these patients probably fulﬁlled the WHO
criteria for SPS.32 CRC was diagnosed in 57 patients (38%).
Current smokers showed a markedly decreased risk of CRC
compared with non-smokers (OR 0.35; 95% CI 0.15 to 0.82).
The authors described this phenomenon as ‘the smoking
paradox’. One of the potential explanations for this paradox is
the hypothesis that the effect of smoking may be mainly
observed on the development of diminutive polyps.32
Therefore, the risk in a given population of patients with
increased CRC risk may be smaller in the smokers than in the
non-smokers. This hypothesis is supported by the fact that in
the current study patients with a history of smoking (current
and former smokers) signiﬁcantly more often fulﬁlled WHO
criterion-3 only, compared with non-smokers (OR 1.7; 95% CI
1.1 to 2.7; p=0.02). This suggests that the pathogenesis of SPS
might be different in smokers and non-smokers, which might
inﬂuence the options for therapy and surveillance for smokers
in the near future. Unfortunately, due to the retrospective
design of this study, a reliable differentiation between current
and former smokers could not be made.
Finally, we showed that the incidence of CRC during non-
structured surveillance is probably lower than assumed in one of
our earlier reports.14 The 5-year cumulative incidence of CRC
during surveillance was 1.5% versus 6.5% that we have reported
earlier.14 Contrary to our prior study, CRCs diagnosed within
the period between SPS diagnosis and the clearing of all relevant
lesions were not accounted as cancers developed during surveil-
lance.14 This strategy aligns with international protocols, which
advice to clear all relevant lesions before the start of CRC sur-
veillance.11 12 This study conﬁrms earlier results from our
group, showing that annual colonoscopy surveillance after the
resection of all clinically relevant lesions is relatively safe.19
The results from this study raise questions about some aspects
of the current WHO guidelines for the diagnosis of SPS.10 In
the current WHO guideline, rectal lesions are excluded from
the clinical diagnostic criteria and in criteria 1 and 2 lesions
in the sigmoid colon are excluded. This seems mainly driven by
the fact that diminutive HPs in the rectosigmoid should prob-
ably not be taken into account for the diagnosis of SPS.
However, results from our study showed that 47.9% of all
CRCs were located in the rectosigmoid. These cancers were
detected in patients who were signiﬁcantly younger than
patients with CRCs located proximal to the rectosigmoid
(median 58.0 vs 63.7; p=0.03). It is not possible to exclude
that a proportion of these CRCs may have arisen from an
adenoma rather than a SP but the substantial proportion of the
CRC arising in the rectosigmoid at a young age implies that
those SPs located in the rectosigmoid are of clinical importance.
It would seem reasonable then to re-assess the WHO criteria
and not exclude lesions purely on their location without taking
into account their size and histopathology. Hopefully these
adjustments to the current WHO guidelines could help in
assigning those patients who are truly at risk of developing
CRC.
Future studies should mainly focus on the safety and feasibil-
ity of personalised treatment and surveillance for patients with
SPS in order to decrease patient burden as well as the incidence
of colonoscopy interval CRCs. The clinical risk factors, as
described in this study, could potentially help to risk stratify
patients with SPS for different surveillance intervals. However,
the low risk of CRC during surveillance could also argue for
prolonged surveillance intervals, for those individuals with and
without CRC risk factors. Furthermore, research should be con-
ducted to evaluate the effect of the discontinuation of smoking
on the polyp burden in patients with SPS. A potential beneﬁcial
result could contribute to provide assistance for patients to quit
smoking.
In conclusion, we showed that SPs containing dysplasia,
advanced adenomas and/or a combined WHO criteria 1 and 3
phenotype are associated with CRC in patients with SPS, while
a history of smoking is inversely associated with CRC in these
patients. Furthermore, we showed that the risk of developing
CRC during non-structural surveillance is lower than earlier
assessed in literature. Future research should focus on the safety
and feasibility of personalised treatment and surveillance for
patients with SPS, in order to decrease patient burden as well as
the number of colonoscopy interval CRCs.
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